ABSTRACT:

Background: Primary retroperitoneal tumors are rare, accounting for less than 1% of malignancies, and are often diagnosed late due to asymptomatic growth. This study presents six cases managed at CHU Ibn Rochd, Casablanca, to highlight diagnostic and therapeutic challenges. 
Methods: Six cases (ages 35–67) included liposarcoma, leiomyosarcoma, neurogenic tumors, undifferentiated sarcoma, lymphoma, and desmoid tumors. Treatments involved surgical resection, chemotherapy, and radiotherapy based on tumor type.
Results: Complete surgical resection was primary treatment, with adjuvant therapy tailored to histology. Outcomes varied, emphasizing the need for rigorous postoperative surveillance to detect recurrence.
Conclusion: A multidisciplinary approach, including early diagnosis, precise surgery, and adjuvant therapy, is essential. Personalized strategies and further research into advanced therapies are needed to improve outcomes in these rare tumors.

KEYWORDS :

Retroperitoneal tumors, Surgery, Surgical resection, Chemotherapy, Radiotherapy.

REFERENCES :

1) Strauss DC, Hayes AJ, Thomas JM. Retroperitoneal sarcoma: the need for a multidisciplinary approach. Ann Surg Oncol. 2011;18(3):693-6.
2) Gronchi A, Lo Vullo S, Fiore M, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol. 2009;27(1):24-30.
3) Bonvalot S, Rivoire M, and Castaing M, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol. 2009;27(1):31-7.
4) Van Dalen T, Hennipman A, Van Coevorden F, et al. Evaluation of a clinically applicable post-surgical classification system for primary retroperitoneal soft-tissue sarcoma. Ann Surg Oncol. 2004;11(5):483-90.
5) Lewis JJ, Leung D, Woodruff JM, et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998;228(3):355-65.
6) Mendenhall WM, Zlotecki RA, Hochwald SN, et al. Retroperitoneal soft tissue sarcoma. Cancer. 2005;104(4):669-75.
7) Singer S, Antonescu CR, Riedel E, et al. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003;238(3):358-70.
8) Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573-81.
9) DeVita VT, Lawrence TS, Rosenberg SA. Cancer: Principles & Practice of Oncology. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2015.
10) Porter GA, Baxter NN, Pisters PW. Retroperitoneal sarcoma: a population-based analysis of epidemiology, surgery, and radiotherapy. Cancer. 2006;106(7):1610-6.
11) Gronchi A, Miceli R, Colombo C, et al. Retroperitoneal soft tissue sarcoma: patterns of care in patients treated at a single institution. Eur J Surg Oncol. 2011;37(2):148-54.
12) Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126-32.
13) Casali PG, Abecassis N, Bauer S, et al. Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv51-iv67.